{"id":"rt001","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting these transporters, RT001 reduces glucose reabsorption in the gut and kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"RT001 is a small molecule drug that targets the SGLT1 and SGLT2 transporters.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:56.841Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04762589","phase":"PHASE2","title":"RT001 in Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Biojiva LLC","startDate":"2021-03-10","conditions":"Amyotrophic Lateral Sclerosis","enrollment":43},{"nctId":"NCT04102501","phase":"PHASE3","title":"A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia","status":"COMPLETED","sponsor":"Biojiva LLC","startDate":"2019-10-30","conditions":"Friedreich's Ataxia","enrollment":65},{"nctId":"NCT03570931","phase":"PHASE2, PHASE3","title":"A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biojiva LLC","startDate":"2018-11-05","conditions":"Infantile Neuroaxonal Dystrophy","enrollment":19},{"nctId":"NCT04937530","phase":"PHASE2","title":"RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY","status":"UNKNOWN","sponsor":"Biojiva LLC","startDate":"2021-06-23","conditions":"Progressive Supranuclear Palsy","enrollment":40},{"nctId":"NCT02445794","phase":"PHASE1, PHASE2","title":"A First in Human Study of RT001 in Patients With Friedreich's Ataxia","status":"COMPLETED","sponsor":"Biojiva LLC","startDate":"2015-08","conditions":"Friedreich's Ataxia","enrollment":19},{"nctId":"NCT01064518","phase":"PHASE2","title":"Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2010-01","conditions":"Lateral Canthal Lines, Crow's Feet, Facial Wrinkles","enrollment":90},{"nctId":"NCT00884234","phase":"PHASE2","title":"Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2009-02","conditions":"Lateral Canthal Lines","enrollment":30},{"nctId":"NCT01124552","phase":"PHASE2","title":"A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2010-04","conditions":"Lateral Canthal Lines, Crow's Feet, Facial Wrinkles","enrollment":180},{"nctId":"NCT00907387","phase":"PHASE2","title":"Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2009-04","conditions":"Lateral Canthal Lines","enrollment":72},{"nctId":"NCT01124565","phase":"PHASE2","title":"Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2010-05","conditions":"Lateral Canthal Lines, Crow's Feet, Facial Wrinkles","enrollment":40},{"nctId":"NCT00888914","phase":"PHASE2","title":"Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2008-11","conditions":"Lateral Canthal Lines, Crow's Feet, Facial Wrinkles","enrollment":60},{"nctId":"NCT00968825","phase":"PHASE2","title":"Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2009-07","conditions":"Lateral Canthal Lines, Crow's Feet, Facial Wrinkles","enrollment":73},{"nctId":"NCT00968942","phase":"PHASE2","title":"Efficacy and Safety Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines","status":"COMPLETED","sponsor":"Revance Therapeutics, Inc.","startDate":"2009-08","conditions":"Lateral Canthal Lines, Crow's Feet, Facial Wrinkles","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["di-deuterated linoleic acid ester","Deuterated linoleic acid"],"phase":"phase_3","status":"active","brandName":"RT001","genericName":"RT001","companyName":"Biojiva LLC","companyId":"biojiva-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RT001 is a small molecule drug that targets the SGLT1 and SGLT2 transporters. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}